Quantifying the diagnostic pathway for patients with cognitive impairment: real-world data from Australia.


Journal

International psychogeriatrics
ISSN: 1741-203X
Titre abrégé: Int Psychogeriatr
Pays: England
ID NLM: 9007918

Informations de publication

Date de publication:
05 2020
Historique:
pubmed: 26 11 2019
medline: 23 11 2021
entrez: 26 11 2019
Statut: ppublish

Résumé

Rapid diagnosis of dementia is essential to ensure optimum patient care. This study used real-world data to quantify the dementia diagnostic pathway in Australia. A real-world, cross-sectional survey of physicians and patients. Clinical practice. Primary care or specialist physicians managing patients with cognitive impairment (CI). Descriptive analyses focused on key events in the diagnostic pathway. Regression modeling compared the duration between first consultation and formal diagnosis with various factors. Data for 600 patients were provided by 60 physicians. Mean time from initial symptoms to first consultation was 6.1 ± 4.4 months; 20% of patients had moderate or severe CI at first consultation. Mean time from first consultation to formal diagnosis was 4.0 ± 7.4 months (1.2 ± 3.6 months if not referred to a secondary physician, and 5.3 ± 8.3 months if referred). Time from first consultation to diagnosis was significantly associated with CI severity at first consultation; time was shorter with more severe CI. There was no association of disease severity and referral to a secondary physician; 69.5% of patients were referred, the majority (57.1%) to a geriatrician. The highest proportion of patients were diagnosed by geriatricians (47.4%). Some form of test or scale was used to aid diagnosis in 98.8% of patients. A substantial number of Australians experience cognitive decline and behavioral changes some time before consulting a physician or being diagnosed with dementia. Increasing public awareness of the importance of early diagnosis is essential to improve the proportion of patients receiving comprehensive support prior to disease progression.

Identifiants

pubmed: 31762429
pii: S1041610219001856
doi: 10.1017/S1041610219001856
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

601-610

Auteurs

Christopher M Black (CM)

Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.

Michael Woodward (M)

Aged Care Services and Head, Aged Care Research, Memory and Wound Clinics, Austin Health, Heidelberg, Victoria, Australia.

Baishali M Ambegaonkar (BM)

Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.

Alana Philips (A)

MSD, Sydney, NSW, Australia.

James Pike (J)

Adelphi Real World, Macclesfield, UK.

Eddie Jones (E)

Adelphi Real World, Macclesfield, UK.

Joseph Husbands (J)

Adelphi Real World, Macclesfield, UK.

Rezaul K Khandker (RK)

Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH